Research Areas

The Oncology area is made up of 14 research groups, around which more than 200 researchers are grouped. This volume of groups and researchers indicates the importance and intensity that research on the problem of cancer implies for ibs.GRANADA itself. The main concern of this Area lies in the need to understand this health problem from very diverse perspectives, since the opportunities to improve its understanding, as well as the strategies to control it, arise from very broad and diverse spaces of knowledge. It is precisely the interaction between the different groups in the area, with their different approaches to the same problem, which will allow progress in the aforementioned aspects, becoming one of our main strengths.

The objectives of the Oncology area are:

a) Promote a transversal and open vision of cancer research approaches, in which basic, clinical and epidemiological research of the highest level is present.

b) Encourage and stimulate cooperation between research groups, which crystallize in projects and collaborative work of a translational nature.

c) Strengthen its lines of research, among which the following should be specifically highlighted:

• The evaluation of results, the quality of healthcare, and integrative oncology
• Environmental contamination and development of neoplasms.
• Research on specific molecular and genetic analysis techniques on predictive factors, biomarkers and immunotherapy in the context of personalized medicine.
• Development of new therapeutic strategies: new antitumor agents, gene therapy strategies and new techniques for the use of radiation and surgical techniques.

The objectives of the area are:

1. Study the effect on the health and quality of life of caregivers women and men.
2. To analyze the variability of clinical practice in the treatment of elderly patients with pressure ulcers.
3. Evaluate the effectiveness of complex health promotion interventions.
4. To study the role of diet and other environmental factors in the etiology of prostate cancer and cardiovascular disease.
5. Study the epidemiology of mental disorder in Andalusia.
6. Investigate the effect of exposures to environmental pollutants on fetal and infant development.
7. To evaluate the sociodemographic factors in health care in chronic diseases.

The area of ​​Precision Medicine is characterized by its marked translational character, in short, by the need to facilitate the transition from basic research into clinical applications that benefit health. This area arose as a need to address the challenge of "personalized medicine" that refers to the adaptation of medical interventions to the individual characteristics of each patient. It is the largest area of ​​the institute including various medical specialties and disciplines involved in translational research for the treatment of diseases.

The objectives of the area are:

a) Define the genetic bases in complex, chronic non-communicable diseases and rare diseases by generating phenotypic data associated with genome, transcriptome, proteome, metabolome, microbiome and exposome data.

b) Study biomarkers of exposure, diagnosis and therapeutic response in complex, chronic non-communicable and rare diseases.

c) Investigate the mechanisms of rare, complex and communicable diseases for the development and evaluation of new therapies: pharmacological (translational studies and clinical trials in different chronic diseases), surgical (Parkinson's disease, tremor, dystonia, epilepsy, hydrocephalus), physical (physiotherapy, mechanical ventilation), endovascular (arrhythmia ablation, cardiac hemodynamics), nutritional and lifestyle, including social and / or psychological aspects (systemic autoimmune diseases, obesity, diabetes, neurodevelopmental and behavioral disorders ...) , as well as healthcare needs and satisfaction with the care received.

The area includes national and international reference groups in the field of pharmacology, advanced therapies, biomaterials and technologies applied to the biosanitary field whose objective is to design and implement new therapies and products that can contribute to the diagnosis or treatment of diseases for which there is no fully effective therapy.
The objectives of the area are:

a) To develop and promote new modulated drugs for the treatment of diseases. Study genetic polymorphisms that affect the efficacy, safety and dosage of drugs. Preparation of clinical practice guidelines. Safe practices in the use of medications. Stability study of drugs in the conditions of clinical use.

b) Generate new Advanced Therapies drugs that allow a treatment based on cell and tissue regeneration. Design new highly biomimetic biomaterials for use in tissue engineering. Implement quality controls at the histological, biomechanical, optical, genetic and functional level of the new products generated for future clinical use. Transfer new advanced therapy products to the clinic in accordance with the standards of the Drug Agencies.

c) Develop new protocols for the treatment of prevalent human pathologies based on new biomedical technologies, advanced surgical techniques, in vitro reproduction, diagnosis through nuclear and molecular medicine and other advanced diagnosis and treatment strategies.